BOTOX Migraine Treatment Failure: What Next?

When BOTOX Doesn’t Work as Expected: Reassessing Chronic Migraine Diagnosis and Preventive Treatment

Two patients walk into their follow-up appointments after completing two treatment cycles of BOTOX® for chronic migraine.

The first patient, Elena, started treatment, experiencing about 20 headache days each month. Six months later, her headache diary shows about nine headache days per month. She still has migraines, but she is using less rescue medication, sleeping more consistently, missing fewer workdays, and participating in family activities she once avoided.

The second patient, Marcus, began with approximately 19 headache days per month. After the same two treatment cycles, his diary still shows 17 to 18 headache days. He also reports frequent use of acute headache medication, persistent neck pain, irregular sleep, and several headaches that do not feel like his previous migraines.

Did BOTOX work for Elena but not for Marcus?

Perhaps. But Marcus’s experience also raises another important possibility: the diagnosis, treatment schedule, medication pattern, overlapping headache disorders, or overall preventive strategy may need to be reassessed.

That distinction matters because BOTOX for chronic migraine is not a one-injection test. Current 2026 migraine-prevention guidance recommends allowing 24 weeks at the recommended dose before assessing the efficacy of onabotulinumtoxinA. Treatment response should also be judged by more than whether headaches disappear completely. Clinicians should consider frequency, severity, migraine-associated symptoms, quality of life, disability, and acute medication use (Potrebic et al., 2026).

For someone who believes BOTOX “isn’t working,” the next clinical question should therefore be more precise:

What is preventing the patient from reaching the expected treatment goal?

What Does an Inadequate BOTOX Response Actually Mean?

BOTOX, or onabotulinumtoxinA, is FDA-approved for prevention of headaches in adults with chronic migraine. U.S. prescribing information describes chronic migraine treatment for adults experiencing at least 15 headache days per month, with headaches lasting four hours a day or longer. The recommended treatment is 155 units distributed among specified head and neck muscles, with retreatment generally occurring every 12 weeks (AbbVie Inc., 2023).

That schedule immediately changes how clinicians should interpret an early response.

A patient who feels little improvement three weeks after the first treatment has not necessarily failed treatment. Even after the first full 12-week cycle, the picture may remain incomplete.

The updated American Academy of Neurology and American Headache Society guideline recommends waiting 24 weeks at the recommended dose before formally assessing BOTOX efficacy for migraine prevention (Potrebic et al., 2026). That corresponds closely to two properly timed treatment cycles.

Earlier European Headache Federation guidance similarly emphasized evaluating more than one cycle and suggested that people without a meaningful response after the first two to three cycles may need reconsideration of treatment. Importantly, that guidance also advised evaluating headache intensity, disability, and patient preferences rather than relying exclusively on headache-day counts (Bendtsen et al., 2018).

So the conversation after two cycles should not simply be:

“Did BOTOX work?”

It should be:

• How many headache days occurred before treatment and now?
• How many days had migraine features?
• Has headache intensity changed?
• Are attacks shorter?
• Is less acute medication needed?
• Has the patient missed fewer work or family activities?
• Has sleep improved?
• Are adverse effects interfering with treatment?
• Did the patient complete both treatment cycles on schedule?
• Does the original diagnosis still explain the patient’s current headache pattern?

That is where a headache diary becomes one of the most useful clinical tools available.

The Headache Diary: Turning “I Don’t Feel Better” Into Clinical Evidence

Migraine treatment can be difficult to judge from memory.

A patient who experiences eight migraines this month may understandably describe the month as terrible. But if that same patient previously experienced 18 migraine days, the treatment may be producing a substantial benefit that is difficult to recognize while symptoms are still occurring.

Conversely, someone may believe the treatment is helping because headaches seem less memorable while the actual monthly frequency remains almost unchanged.

A consistent headache diary reduces this uncertainty.

The 2026 AAN/AHS guideline specifically recommends documenting migraine frequency and notes that clinicians may consistently use tools such as a headache diary, the Headache Impact Test-6, or the Migraine Disability Assessment Scale to monitor treatment response (Potrebic et al., 2026).

A useful diary may record:

• Any headache day
• Days with migraine symptoms
• Headache duration
• Pain intensity
• Nausea, light sensitivity, sound sensitivity, aura, or dizziness
• Acute medications taken
• Whether medication helped
• Sleep disruption
• Menstrual or hormonal patterns when relevant
• Neck pain or musculoskeletal symptoms
• Missed work, exercise, school, or family activities

This kind of record helps clinicians distinguish a true lack of response from an incomplete response—and it can reveal an entirely different problem.

Marcus’s Diary Reveals a Clue

Return to Marcus, our hypothetical patient.

His monthly headache frequency has barely changed after two treatment cycles. But his diary contains another important pattern: he takes an acute headache medication on many days each month.

That immediately raises the possibility of medication-overuse headache.

The International Classification of Headache Disorders, Third Edition, describes medication-overuse headache as a headache occurring on at least 15 days per month in a person with a pre-existing headache disorder who regularly overuses acute or symptomatic headache medication for more than three months. The specific overuse threshold varies by medication category. Importantly, patients can meet diagnostic criteria for both chronic migraine and medication-overuse headache (International Headache Society, n.d.).

This does not mean the patient intentionally misuses medication.

Someone living with frequent migraines may simply be trying to function.

A tablet helps on Monday, so the patient uses it again Wednesday. Another attack appears Friday. Soon, acute medications are being taken frequently enough that the medication pattern itself becomes clinically relevant.

That is why medication reconciliation is essential when preventive therapy appears ineffective.

Review Everything the Patient Is Taking

Clinicians evaluating an inadequate response should review prescription medications, over-the-counter medications, supplements, and medications prescribed by other clinicians.

Questions may include:

How frequently are triptans, gepants, NSAIDs, acetaminophen-containing products, combination headache medications, or other rescue therapies being used?

Has another preventive medication been started or stopped?

Has a medication changed the headache pattern?

Is the patient taking a muscle relaxant?

Has the patient recently received another botulinum toxin product?

Are several physicians prescribing medications without each having the complete medication list?

For BOTOX specifically, prescribing information warns that patients receiving aminoglycoside antibiotics, medications that interfere with neuromuscular transmission, or muscle relaxants should be observed carefully because BOTOX’s effects may be potentiated. BOTOX potency units are also product-specific and cannot be directly converted to those of other botulinum toxin preparations (AbbVie Inc., 2023).

Medication review is therefore not just paperwork performed around the treatment.

It is part of the treatment.

Medication-Overuse Headache Does Not Automatically Exclude Prevention

Discovering medication overuse also does not necessarily mean preventive treatment must be abandoned.

The 2026 migraine-prevention guideline specifically recommends offering preventive medication to people who have medication overuse or medication-overuse headache. It identifies onabotulinumtoxinA as a preventive treatment with evidence of efficacy in individuals with these problems (Potrebic et al., 2026).

The treatment plan may instead need to address both sides of the problem:

reducing migraine susceptibility through appropriate prevention while developing a safe strategy for excessive acute-medication use.

That process should be individualized because medication categories, withdrawal risks, medical history, and alternative rescue options differ among patients.

Marcus may therefore have something more complicated than “BOTOX failure.”

His preventive treatment may be operating in the middle of an unresolved medication-use pattern that needs attention.

Reconsider the Chronic Migraine Diagnosis

A second major question is whether the patient’s headaches still fit the diagnosis being treated.

Under ICHD-3 criteria, chronic migraine generally involves headache on at least 15 days per month for more than three months, with migraine characteristics present on at least eight days per month, in a person with an appropriate migraine history. The headache pattern should not be better accounted for by another ICHD-3 diagnosis (International Headache Society, n.d.).

The final phrase is extremely important:

not better accounted for by another diagnosis.

Patients often use the word “migraine” to describe almost any severe headache. Clinicians must be more specific.

A person may have a migraine plus another headache disorder. Symptoms can overlap with tension-type headache, cervicogenic headache, occipital neuralgia, post-traumatic headache, temporomandibular pain, medication-overuse headache, or other primary and secondary headache conditions.

Someone involved in a motor vehicle collision may also have a pre-existing migraine disorder plus cervical soft-tissue injury. Another patient may experience headache pain referred from irritated cervical structures while still having genuine migraine attacks.

These distinctions matter because treating one mechanism does not guarantee that another source of head or neck pain will disappear.

When Neck Pain and Migraine Overlap

Neck pain deserves particular attention because it can coexist with migraine without necessarily causing the migraine disorder.

For a patient like Marcus, clinicians may need to ask whether his remaining symptoms represent persistent migraine, cervical musculoskeletal pain, another headache type, or several overlapping problems.

This is where multidisciplinary evaluation can be useful.

A medical migraine-prevention strategy may address chronic migraine while musculoskeletal examination evaluates cervical motion, muscle guarding, tenderness, posture, previous whiplash, or other clinically relevant findings.

When appropriate, rehabilitation, chiropractic care, acupuncture, electroacupuncture, exercise, or other nonpharmacological strategies may be considered for selected musculoskeletal complaints or as components of an individualized integrative plan. They should not be represented as replacements for an established neurological diagnosis or evidence-based migraine prevention.

The goal is to determine what each treatment is actually being asked to treat.

That protects the patient from repeatedly adding procedures without identifying why symptoms remain.

Was the BOTOX Treatment Schedule Actually Completed?

Preventive therapy also needs a fair clinical trial.

U.S. prescribing information recommends retreatment approximately every 12 weeks for chronic migraine (AbbVie Inc., 2023).

If a patient’s second appointment occurs substantially later because of scheduling problems, insurance authorization, illness, travel, or a missed visit, the treatment history may no longer mirror the evidence-based schedule.

Similarly, clinicians should verify that the patient actually completed both treatment cycles rather than assuming that an ordered treatment was administered.

This sounds simple, but adherence matters.

The 2026 guideline emphasizes adherence as an important factor in preventive treatment outcomes and recommends considering inconsistent adherence and frequent trigger exposure when efficacy appears poor (Potrebic et al., 2026).

Before labeling someone a nonresponder, clinicians should therefore establish whether the treatment received was reasonably comparable to the treatment being evaluated.

Adverse Effects Can Change the Risk-Benefit Decision

Treatment can reduce migraine frequency and still be unacceptable to the patient.

In chronic migraine clinical trials summarized in BOTOX prescribing information, reported adverse reactions included neck pain, headache, eyelid drooping, muscular weakness, musculoskeletal stiffness, muscle pain, injection-site pain, and several less common effects. Neck pain occurred in about 9% of BOTOX-treated patients compared with 3% receiving placebo. Eyelid ptosis occurred in about 4% compared with less than 1% with placebo (AbbVie Inc., 2023).

The prescribing information also includes a boxed warning about the possible distant spread of botulinum toxin effects. Patients should seek immediate medical attention if significant swallowing, speech, or breathing difficulties occur after treatment (AbbVie Inc., 2023).

For most patients reassessing therapy, the discussion is less dramatic.

• Perhaps headache frequency decreased, but persistent neck weakness is affecting work.
• Perhaps the benefit lasts only part of the treatment interval.
• Perhaps injections produce enough anxiety or discomfort that the patient no longer considers the benefit worthwhile.

Patient autonomy matters here.

A statistically measurable response is not automatically the same as a treatment the individual wants to continue.

Elena Is a Responder Even Though She Still Has Migraines

Now reconsider Elena.

She has gone from approximately 20 monthly headache days to nine.

She still gets migraines.

That does not mean treatment failed.

Her acute-medication use has decreased, she sleeps more consistently, she misses fewer days at work, and family activities are no longer being canceled as frequently.

Current migraine guidance emphasizes this patient-centered view of efficacy. Clinicians should consider migraine frequency, severity, associated symptoms, quality of life, and acute-treatment use when determining whether prevention is working (Potrebic et al., 2026).

Elena’s outcome demonstrates an important expectation for patients:

Preventive treatment is intended to reduce migraine burden. It does not guarantee complete elimination of every migraine attack.

The meaningful result may be getting part of life back.

Marcus Needs a Diagnostic Review, Not a Reflexive Third Procedure

Marcus’s situation is different.

After approximately 24 weeks, his headache frequency has changed very little.

His diary suggests frequent acute-medication use.

Some headaches now feel different from his usual migraines.

Persistent cervical symptoms are present.

This is the point where the clinical team should reconsider assumptions.

Potential questions include whether he continues to meet the expected chronic migraine pattern, whether medication-overuse headache is present, whether another headache disorder is coexisting, whether treatment sessions followed the intended schedule, whether lifestyle factors are significantly interfering with prevention, and whether adverse effects or concurrent medications have complicated treatment.

If the response remains suboptimal after an appropriate trial, the 2026 guideline recommends shared decision-making about moving to an alternative preventive treatment when suitable alternatives are available and not contraindicated (Potrebic et al., 2026).

Depending on diagnosis and individual medical factors, preventive options may include CGRP-targeting therapies, atogepant, topiramate, or other evidence-supported medications.

The correct choice depends on medical history, contraindications, medication interactions, pregnancy considerations, side-effect priorities, insurance coverage, previous therapies, and patient preferences.

Changing strategy is not the same thing as giving up.

Sometimes a treatment response provides information that helps refine the diagnosis.

What Makes Dr. Jimenez’s Injury Medical Chiropractic and Functional Medicine Clinic Different?

Injury Medical Chiropractic and Functional Medicine Clinic in El Paso uses a multidisciplinary model that can be particularly useful when migraine symptoms overlap with musculoskeletal injury, cervical pain, sleep problems, medication concerns, metabolic conditions, or rehabilitation needs.

Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, is dual-licensed as a Doctor of Chiropractic and board-certified Family Practice Nurse Practitioner. His clinical work bridges musculoskeletal and soft-tissue injury evaluation, physical medicine, rehabilitation, functional-health assessment, and medical evaluation within his licensed scope. The clinic’s current public information specifically lists migraine BOTOX among the services it provides.

Dr. Maria Guadalupe Cardenas, MD, is board-certified in internal medicine and serves as medical director, clinical director, and collaborative physician. The clinic identifies her Texas medical license as J2933 and NPI as 1164426748. Dr. Jimenez’s Texas APRN/FNP license is listed as 1191402, with NPI 1205907805.

This clinical model does not distinguish itself by offering BOTOX exclusively. Other El Paso medical practices also offer BOTOX for chronic migraine. Rather, the difference is the ability to evaluate migraine prevention alongside soft-tissue injury, cervical biomechanics, rehabilitation, medical comorbidities, and functional-health concerns within a coordinated multidisciplinary setting.

This approach reflects three important bioethical principles.

Beneficence means choosing interventions because they are reasonably expected to help that particular patient—not simply because the treatment is available. Migraine prevention, rehabilitation, appropriately selected chiropractic care, acupuncture or electroacupuncture, and medical evaluation should each have a defined clinical purpose.

Non-maleficence means recognizing contraindications, medication interactions, adverse effects, neurological warning signs, and circumstances in which another treatment—or referral to another specialist—is safer than continuing the same approach.

Autonomy means giving patients understandable information about benefits, limitations, risks, alternatives, costs, and reasonable expectations so they remain the informed decision-makers in their care. Patients should also be able to coordinate treatment seamlessly with their neurologist, primary-care physician, gynecologist, pain specialist, or other established clinicians.

Sometimes “BOTOX Didn’t Work” Is the Beginning of Better Migraine Care

The difference between Elena and Marcus shows why treatment response matters.

Elena’s continued migraines do not erase the substantial reduction in headache days and improvement in daily function.

Marcus’s disappointing response does not automatically mean nothing can help him.

Instead, his experience tells the clinical team where to look next.

Review the diary.

Confirm the treatment timeline.

Reconcile medications.

Look for medication overuse.

Revisit the diagnosis.

Consider coexisting headache disorders.

Evaluate persistent neck or soft-tissue complaints separately.

Discuss adverse effects.

Measure disability and quality of life.

Then decide—with the patient—whether continuing BOTOX, changing prevention, addressing another contributor, or obtaining additional specialty evaluation makes the most sense.

Migraine prevention works best when the treatment plan remains flexible enough to respond to the evidence generated by the patient.

The objective is not to defend a particular procedure.

It is to help the patient experience fewer disabling headache days, greater physical function, more predictable sleep, less reliance on rescue treatment, and more freedom to participate in everyday life.

Related Resources

• For readers wanting a deeper explanation of patient selection, dosing, and the 2026 guidelines, see the BOTOX Chronic Migraine Treatment: 2026 Clinical Guide
• For a broader multidisciplinary perspective, see Integrated Migraine Treatment El Paso: Complete Clinical Guide.
• For patient-oriented information on migraine management, headache diaries, lifestyle approaches, and integrative options, see Migraine Treatment and Headaches and Treatment.

---

References

AbbVie Inc. (2023). BOTOX® (onabotulinumtoxinA) prescribing information. BOTOX Prescribing Information

Bendtsen, L., Sacco, S., Ashina, M., Mitsikostas, D., Ahmed, F., Pozo-Rosich, P., & Martelletti, P. (2018). Guideline on the use of onabotulinumtoxinA in chronic migraine: A consensus statement from the European Headache Federation. The Journal of Headache and Pain, 19(1), 91. Guideline on the Use of OnabotulinumtoxinA in Chronic Migraine

International Headache Society. (n.d.). 1.3 Chronic migraine. International Classification of Headache Disorders, 3rd edition. ICHD-3 Chronic Migraine Criteria

International Headache Society. (n.d.). 8.2 Medication-overuse headache (MOH). International Classification of Headache Disorders, 3rd edition. ICHD-3 Medication-Overuse Headache Criteria

Potrebic, S., Tanveer, S., Becker, W. J., Burch, R., Cooke, L. J., Fenton, T., Fletcher, J. J., Gordon Perue, G. L., Hershey, A. D., Jackson, J. L., Kessel, S., Loder, E. W., Minen, M. T., Oskoui, M., Ramanan, V. K., Murren, M., Schwedt, T. J., Silberstein, S. D., Smith, D. B., . . . Pringsheim, T. (2026). Pharmacologic treatment for migraine prevention in adults practice guideline recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society. Neurology, 107(7), e214881. 2026 AAN/AHS Migraine Prevention Guideline

Medical Disclaimer: This article is intended for educational purposes and does not provide individualized diagnosis or treatment recommendations. Chronic migraine, medication-overuse headache, eligibility for BOTOX, medication changes, and persistent or changing headache symptoms should be evaluated by an appropriately licensed healthcare professional. Patients with sudden severe headache, new neurological deficits, significant difficulty speaking or swallowing, breathing difficulty, altered consciousness, or other concerning new symptoms should seek prompt medical attention.